What is the 13F Pro Quality Score for TVTX?

13F Pro ranks Travere Therapeutics, Inc. (TVTX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TVTX's current score at https://13fpro.ai/research/TVTX (free sign-up required for the full ranking).

Which hedge funds own the most TVTX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of TVTX include JANUS HENDERSON GROUP PLC, FMR, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/TVTX as soon as new 13F filings post.

Where does 13F Pro source TVTX data?

All Travere Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Travere Therapeutics, Inc. files with the SEC under CIK 1438533. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TVTX in?

Travere Therapeutics, Inc. (TVTX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is TVTX research updated on 13F Pro?

TVTX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Travere Therapeutics, Inc.(TVTX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1438533 TVTX stock profile & AI dashboard →

13F Pro Quality Score

39.2/100

Rank #1,981 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

95.3/100

Profitability

24.0/100

Balance Sheet

16.6/100

Earnings Quality

30.0/100

Free Cash Flow

17.0/100

Institutional Flow

48.6/100

Revenue Scale

36.6/100

Dilution Risk

17.9/100

TVTX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Travere Therapeutics, Inc. (TVTX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TVTX at 39.2/100 on a 32-signal composite quality model, placing it at rank #1,981 of 2,879 stocks — the bottom half of the AI-ranked universe. TVTX scores in the top quartile across revenue growth (95.3). Areas of concern include balance sheet strength (16.6) and free cash flow (17.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 17.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Travere Therapeutics, Inc. reports quarterly revenue of $127.2M, net income of $-37.1M, free cash flow of $-40.4M. Top institutional holders of TVTX by reported 13-F value include JANUS HENDERSON GROUP PLC, FMR, BlackRock,, based on the most recent SEC filings. TVTX trades on the Nasdaq exchange and files with the SEC under CIK 1438533. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TVTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Travere Therapeutics, Inc. directly from SEC EDGAR. Travere Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 8 and 79 since 2021, currently 39.2 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about Travere Therapeutics, Inc.

Quirks, history, and lore behind TVTX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in San Diego, California.
2
The Numbers
Annual revenue in the low hundreds of millions of dollars, with a commercial-stage pipeline focused on a narrow slice of rare kidney and metabolic diseases.
3
The History
The company rebranded around 2021 to better reflect its mission, shedding an older identity and doubling down on treatments for rare, life-threatening conditions with few existing options.
4
The Secret
Its crown-jewel program targets IgA nephropathy — a rare autoimmune kidney disease that quietly destroys renal function — an area that was long ignored by big pharma.
5
The Lore
The FDA granted its lead drug Accelerated Approval for IgA nephropathy, making it one of the first treatments ever approved for a disease that affects roughly 150,000 Americans.
6
The Giveaway
Its approved therapy sparsentan (brand name Filspari) treats a rare kidney condition, and the company's ticker is just four letters that rhyme with a certain cable TV network.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$127.2M

Net Income

Q1 2026

$-37.1M

Free Cash Flow

Q1 2026

$-40.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+110.5% YoY

$490.7MFY 2025

FY20 $198.3MFY23 $145.2MFY24 $233.2MFY25 $490.7M

Net Income

+92.1% YoY

$-25.5MFY 2025

FY20 $-169.4MFY23 $-111.4MFY24 $-321.5MFY25 $-25.5M

Operating Income

+80.6% YoY

$-62.8MFY 2025

FY20 $-176.2MFY23 $-388.1MFY24 $-323.8MFY25 $-62.8M

EPS (Diluted)

+92.9% YoY

$-0.29FY 2025

FY20 $-3.56FY23 $-1.50FY24 $-4.08FY25 $-0.29

Total Assets

+1.9% YoY

$605.2MFY 2025

FY20 $607.4MFY23 $788.9MFY24 $594.1MFY25 $605.2M

Op. Cash Flow

+115.9% YoY

$37.8MFY 2025

FY20 $-42.7MFY23 $-280.0MFY24 $-237.5MFY25 $37.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2020	FY 2019	FY 2017
Revenue	$490.7M +110.5%	$233.2M +60.5%	$145.2M -26.8%	$198.3M +13.1%	$175.3M +13.2%	$154.9M
Net Income	$-25.5M +92.1%	$-321.5M -188.6%	$-111.4M +34.3%	$-169.4M -15.7%	$-146.4M -145.1%	$-59.7M
Operating Income	$-62.8M +80.6%	$-323.8M +16.6%	$-388.1M -120.3%	$-176.2M -28.2%	$-137.4M -155.4%	$-53.8M
EPS (Diluted)	$-0.29 +92.9%	$-4.08 -172.0%	$-1.50 +57.9%	$-3.56 -2.9%	$-3.46 -124.7%	$-1.54
Total Assets	$605.2M +1.9%	$594.1M -24.7%	$788.9M +29.9%	$607.4M +0.4%	$604.8M +16.2%	$520.3M
Operating Cash Flow	$37.8M +115.9%	$-237.5M +15.2%	$-280.0M -555.1%	$-42.7M +26.6%	$-58.2M -886.4%	$7.4M

AI Insight: TVTX Ratio Trends

Travere's margins remain deeply negative in Q1 2026 after a single profitable quarter in Q3 2025, signaling no durable profitability inflection yet.

• Operating margin improved sharply from -125.1% in Q2 2024 to -11.1% in Q2 2025, showing meaningful cost/revenue progress over four quarters.

• Q3 2025 was the only profitable quarter in the dataset, with operating margin of 15.1% and NPM of 15.6%, but reversed sharply in Q4 2025 and Q1 2026.

• Q1 2026 operating margin deteriorated to -29.0% and ROA to -26.7%, reversing the improvement trend seen through mid-2025.

• TTM operating margin of -10.6% and NPM of -4.0% reflect that the Q3 2025 profit was insufficient to offset surrounding quarterly losses.

⚠ Q1 2026 ROE collapsed to -150.3% from 9.5% in Q4 2025 — monitor whether this reflects a one-off charge or renewed structural losses.

⚠ D/E is unavailable across all periods; leverage visibility is a key missing input for assessing balance sheet risk.

⚠ Whether Q3 2025 profitability can be sustained or was a one-time event is the critical inflection to track over coming quarters.

Get alerted when TVTX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Travere Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TVTX

JANUS HENDERSON GROUP PLC
$339.2M11,419,586 sh
FMR LLC
$325.9M10,967,967 sh
BlackRock, Inc.
$231.5M7,792,033 sh
STATE STREET CORP
$147.4M4,959,988 sh
ARMISTICE CAPITAL, LLC
$145.5M4,897,417 sh
LINDEN ADVISORS LP
$127.9M101,062,000 sh
PERCEPTIVE ADVISORS LLC
$123.1M4,142,551 sh
VANGUARD CAPITAL MANAGEMENT LLC
$120.2M4,045,812 sh
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.
$97.2M3,270,513 sh
GEODE CAPITAL MANAGEMENT, LLC
$70.4M2,369,559 sh

Fund	Value	Shares
JANUS HENDERSON GROUP PLC	$339.2M	11,419,586
FMR LLC	$325.9M	10,967,967
BlackRock, Inc.	$231.5M	7,792,033
STATE STREET CORP	$147.4M	4,959,988
ARMISTICE CAPITAL, LLC	$145.5M	4,897,417
LINDEN ADVISORS LP	$127.9M	101,062,000
PERCEPTIVE ADVISORS LLC	$123.1M	4,142,551
VANGUARD CAPITAL MANAGEMENT LLC	$120.2M	4,045,812
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.	$97.2M	3,270,513
GEODE CAPITAL MANAGEMENT, LLC	$70.4M	2,369,559

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TVTX on your watchlist

Track score changes the day Travere Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TVTX a good stock to buy?

13F Pro's AI-powered analysis of Travere Therapeutics, Inc. (TVTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TVTX are available on the TVTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own TVTX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TVTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Travere Therapeutics, Inc.'s investment landscape.